Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.48 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15705177 | 1.00 | SIGMAR1 (0.48) | SIGMAR1TAAR1SLC18A2SLC6A2MAOA | |
| SCHEMBL12050576 | 1.00 | SIGMAR1 (0.48) | SIGMAR1TAAR1SLC18A2SLC6A2MAOA | |
| SCHEMBL14600528 | 1.00 | SIGMAR1 (0.48) | SIGMAR1TAAR1SLC18A2SLC6A2MAOA | |
| SCHEMBL13140814 | 0.84 | SIGMAR1 (0.38) | SIGMAR1TAAR1SLC18A2SLC6A2MAOA | |
| SCHEMBL13118761 | 0.84 | SIGMAR1 (0.38) | SIGMAR1TAAR1SLC18A2SLC6A2MAOA | |
| SCHEMBL14479839 | 0.84 | SIGMAR1 (0.38) | SIGMAR1TAAR1SLC18A2SLC6A2MAOA | |
| SCHEMBL14390775 | 0.82 | EPHX1 (0.41) | SIGMAR1TAAR1SLC6A2MAOASLC6A4 | |
| SCHEMBL12327092 | 0.82 | SIGMAR1 (0.37) | SIGMAR1TAAR1SLC18A2 | |
| SCHEMBL6443708 | 0.79 | MOGAT2 (0.38) | SIGMAR1 | |
| SCHEMBL13536230 | 0.79 | CTRB1 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580981-B2 | Process for the preparation of (3R,3aS,6aR)-hexahydrofuro [2,3-b] furan-3-yl (1S,2R)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate | JANSSEN R&D IRELAND (IE) | 2013-11-12 | — | — | US | disclosed |
| US-8143421-B2 | Broadspectrum substituted benzimidazole sulfonamide HIV protease inhibitors | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2012-03-27 | — | — | US | disclosed |
| US-8076513-B2 | Methods for the preparation of N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl)-p-nitrobenzenesulfonylamide derivatives | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-12-13 | — | — | US | disclosed |
| US-20110160468-A1 | PROCESS FOR THE PREPARATION OF (3R,3AS,6AR)-HEXAHYDROFURO [2,3-B] FURAN-3-YL (1S,2R)-3-[[(4-AMINOPHENYL) SULFONYL] (ISOBUTYL) AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE | JANSSEN SCIENCES IRELAND UC (IE) | 2011-06-30 | — | — | US | disclosed |
| US-7763641-B2 | Broadspectrum heterocyclic substituted phenyl containing sulfonamide HIV protease inhibitors | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2010-07-27 | — | — | US | disclosed |
| US-20100121094-A1 | METHODS FOR THE PREPARATION OF N-ISOBUTYL-N-(2-HYDROXY-3-AMINO-4-PHENYLBUTYL)-P-NITROBENZENESULFONYLAMIDE DERIVATIVES | TIBOTEC PHARMACEUTICALS LTD | 2010-05-13 | — | — | US | disclosed |
| US-20090203743-A1 | SMALL MOLECULE ENTRY INHIBITORS | SURLERAUX DOMINIQUE LOUIS | 2009-08-13 | — | — | US | disclosed |
| US-20080132552-A1 | N-methyl hydroxyethylamine useful in treating CNS conditions | PFIZER INC. | 2008-06-05 | — | — | US | disclosed |
| US-20070213368-A1 | N-ETHYL HYDROXYETHYLAMINE USEFUL IN TREATING CNS CONDITIONS | KLEINMAN EDWARD F | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160468-A1 | PROCESS FOR THE PREPARATION OF (3R,3AS,6AR)-HEXAHYDROFURO [2,3-B] FURAN-3-YL (1S,2R)-3-[[(4-AMINOPHENYL) SULFONYL] (ISOBUTYL) AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE | HTR3C, HPD, HAAO | SIGMAR1 1217/4885TAAR1 3998/4885SLC18A2 4146/4885 |
| US-20070213368-A1 | N-ETHYL HYDROXYETHYLAMINE USEFUL IN TREATING CNS CONDITIONS | HNMT, PNMT, NEFM | SIGMAR1 431/4885TAAR1 154/4885SLC18A2 9/4885 |
| US-20090203743-A1 | SMALL MOLECULE ENTRY INHIBITORS | NR0B1, LTC4S, LTB4R | SIGMAR1 596/4885TAAR1 268/4885SLC18A2 1532/4885 |
| US-20080132552-A1 | N-methyl hydroxyethylamine useful in treating CNS conditions | HNMT, PNMT, BHMT | SIGMAR1 390/4885TAAR1 128/4885SLC18A2 8/4885 |
| US-20100121094-A1 | METHODS FOR THE PREPARATION OF N-ISOBUTYL-N-(2-HYDROXY-3-AMINO-4-PHENYLBUTYL)-P-NITROBENZENESULFONYLAMIDE DERIVATIVES | DNPEP, NPEPPS, ASNS | SIGMAR1 2595/4885TAAR1 4703/4885SLC18A2 4431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.